AlphaFold predicted structure
AGPAT3 · Q9NRZ7

Mean pLDDT
94.6/ 100
Very high
376 residues
Confidence breakdown
- Very high(≥ 90)94%
- Confident(70–90)3%
- Low(50–70)2%
- Very low(< 50)2%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
1-acylglycerol-3-phosphate O-acyltransferase 3
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Intellectual disability
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
prostate carcinoma
drug allergy
neurodevelopmental disorder
inherited retinal dystrophy
adverse effect
idiopathic generalized epilepsy
tooth disorder
retinitis pigmentosa
Cone rod dystrophy
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
1-acyl-sn-glycerol-3-phosphate acyltransferase gamma
Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone (PubMed:21173190). Acts on LPA containing saturated or unsaturated fatty acids C16:0-C20:4 at the sn-1 position using C18:1, C20:4 or C18:2-CoA as the acyl donor (PubMed:21173190). Also acts on lysophosphatidylcholine, lysophosphatidylinositol and lysophosphatidylserine using C18:1 or C20:4-CoA (PubMed:21173190). Has a preference for arachidonoyl-CoA as a donor (By similarity). Also has a modest lysophosphatidylinositol acyltransferase (LPIAT) activity, converts lysophosphatidylinositol (LPI) into phosphatidylinositol (By similarity)
AGPAT3 · Q9NRZ7

Mean pLDDT
94.6/ 100
Very high
376 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0